Replies to post #211169 on Biotech Values

[DewDiligence]

MRK/(BMY)—The BLA is not quite a slam dunk insofar as the supporting data are from a single cohort (123 patients) of a phase-2 trial (KEYNOTE-021) where the OS data have not yet matured:

https://www.clinicaltrials.gov/ct2/show/NCT02039674 (cohort G)